Zanubrutinib for Mantle Cell Lymphoma User Reviews
Brand names: Brukinsa
Zanubrutinib has an average rating of 8.0 out of 10 from a total of 3 reviews for the treatment of Mantle Cell Lymphoma. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
- Owen
- Taken for 1 to 6 months
- December 5, 2022
"So far iIhave little side effects , and waiting for a PET test to see if I have good results , I am only in week 9 yet , but I feel good."
- raf
- Taken for 1 to 6 months
- January 27, 2024
Brukinsa (zanubrutinib) "Other than tingling of skin in my arms and occasional red spots that go away in about a week, I feel good."
Frequently asked questions
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about zanubrutinib
- Check interactions
- Compare alternatives
- Reviews (20)
- Side effects
- Dosage information
- During pregnancy
- Drug class: BTK inhibitors
- Breastfeeding
- En español
Brukinsa (zanubrutinib) "Brukinsa put me in remission within a 6-month timeframe of starting the treatment. Benefits are it has kept me in remission for almost 12 months. Very pleased with the results. As for side effects, I've experienced rashes, musculoskeletal pain, muscle spasms, fatigue, and occasional stomach constipation or diarrhea. I take 320 mg per day, 2 in the morning and 2 in the evening."